U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H30O3
Molecular Weight 306.4397
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXANDROLONE

SMILES

C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C

InChI

InChIKey=QSLJIVKCVHQPLV-PEMPUTJUSA-N
InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H30O3
Molecular Weight 306.4397
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Oxandrolone is a synthetic, orally active anabolic-androgenic steroid. Oxandrolones interact with androgen receptors in target tissues. Oxandrin is indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis. Side effects include: elevated aminotransferases (ALT, AST), lipid abnormalities (e.g., decreased HDL cholesterol concentrations). Cardiovascular side effects have included edema, with and without congestive heart failure. Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
62.0 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
OXANDRIN
Secondary
OXANDRIN

Cmax

ValueDoseCo-administeredAnalytePopulation
23 ng/mL
0.2 mg/kg single, buccal
OXANDROLONE plasma
Homo sapiens
44.6 ng/mL
10 mg single, buccal
OXANDROLONE plasma
Homo sapiens
15.1 ng/mL
0.1 mg/kg 2 times / day multiple, buccal
OXANDROLONE plasma
Homo sapiens
417 ng/mL
10 mg single, oral
OXANDROLONE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
58.6 ng × h/mL
0.2 mg/kg single, buccal
OXANDROLONE plasma
Homo sapiens
249 ng × h/mL
10 mg single, buccal
OXANDROLONE plasma
Homo sapiens
36.9 ng × h/mL
0.1 mg/kg 2 times / day multiple, buccal
OXANDROLONE plasma
Homo sapiens
3380 ng × h/mL
10 mg single, oral
OXANDROLONE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
2.87 h
0.2 mg/kg single, buccal
OXANDROLONE plasma
Homo sapiens
2.19 h
0.1 mg/kg 2 times / day multiple, buccal
OXANDROLONE plasma
Homo sapiens
9.4 h
10 mg single, oral
OXANDROLONE plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

PubMed

Sample Use Guides

In Vivo Use Guide
The daily adult dosage is 2.5 mg to 20 mg given in 2 to 4 divided doses. The desired response may be achieved with as little as 2.5 mg or as much as 20 mg daily. A course of therapy of 2 to 4 weeks is usually adequate.
Route of Administration: Oral
In Vitro Use Guide
Dimerization and DNA binding of the AR fragments were observed at 0.5–1 uM oxandrolone.
Substance Class Chemical
Record UNII
7H6TM3CT4L
Record Status Validated (UNII)
Record Version